【诺和诺德口服减重药物获欧盟委员会批准】当地时间7月15日,丹麦制药商诺和诺德宣布,欧盟委员会已批准Wegovy®口服片剂上市,用于治疗肥胖或超重且至少伴有一种体重相关合并症的成人,作为低热量饮食和增加体力活动的辅助手段。Wegovy®口服片剂也成为欧盟首个用于体重管理的口服GLP-1药物。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.